News

Genprex Provides Clinical and Corporate Update for Third Quarter 2018

AUSTIN, Texas--(BUSINESS WIRE)--Nov. 20, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update

Read More

Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN

Read More

How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer

The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.

Read More

Genprex, Inc. Commences Initial Public Offering And Sets Price

AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ -- Genprex, Inc., ("Genprex") a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share.

Read More

Genprex to Present at Upcoming Investor and Industry Conferences

AUSTIN,Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

How gene therapy is reprogramming the course of lung cancer

How gene therapy is reprogramming the course of lung cancer

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Read More

Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

AUSTIN, Texas & CAMBRIDGE, Mass.--Sept. 6, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 28, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today
Read More

Genprex to Present at Upcoming Investor Conferences

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link